Tu HB, Chen LH, Huang YJ, Feng SY, Lin JL, Zeng YY. Novel model combining contrast-enhanced ultrasound with serology predicts hepatocellular carcinoma recurrence after hepatectomy. World J Clin Cases 2021; 9(24): 7009-7021 [PMID: 34540956 DOI: 10.12998/wjcc.v9.i24.7009]
Corresponding Author of This Article
Yong-Yi Zeng, MD, PhD, Professor, Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, No. 312 Xihong Road, Fuzhou 350025, Fujian Province, China. lamp197311@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hai-Bin Tu, Li-Hong Chen, Yu-Jie Huang, Si-Yi Feng, Jian-Ling Lin, Department of Ultrasound, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, Fujian Province, China
Yong-Yi Zeng, Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, Fujian Province, China
Author contributions: Tu HB designed and performed the research, and wrote and analyzed the paper; Chen LH, Huang YJ, and Feng SY designed the research, collected the data, and supervised the report; Lin JL provided clinical advice; and Zeng YY supervised the report.
Supported byStartup Fund for Scientific Research, Fujian Medical University, No. 2019QH1302.
Institutional review board statement: The study was reviewed and approved by the Mengchao Hepatobiliary Hospital of Fujian Medical University Institutional Review Board (No. 2010_010_01).
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Yi Zeng, MD, PhD, Professor, Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, No. 312 Xihong Road, Fuzhou 350025, Fujian Province, China. lamp197311@126.com
Received: March 13, 2021 Peer-review started: March 13, 2021 First decision: June 3, 2021 Revised: June 12, 2021 Accepted: July 5, 2021 Article in press: July 5, 2021 Published online: August 26, 2021 Processing time: 163 Days and 12.6 Hours
Core Tip
Core Tip: This study aimed to construct and verify a non-invasive prediction model combining contrast-enhanced ultrasound with serology biomarkers to predict the early recurrence of hepatocellular carcinoma. Records of 292 local patients of hepatocellular carcinoma (HCC) were selected for analysis. A nomogram predicting early recurrence (ER) named contrasted-enhanced ultrasound (CEUS) model, incorporating tumor diameter, preoperative alpha-fetoprotein level, and LIRADS, was developed. The model showed satisfactory results, and the C-index was 0.762 (95%CI: 0.706–0.819). The calibration at 6 mo was desirable. The CEUS model enables the well-calibrated individualized prediction of ER before surgery and may represent a novel tool for biomarker research and individual counseling.
